The value of surveillance and other unresolved issues in the management of Barrett's esophagus

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 2, Issue 2, 2005, Pages 60-61

  Playford, Raymond J ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; PROTON PUMP INHIBITOR;

ANAMNESIS; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER SCREENING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS SURGERY; FOLLOW UP; HEALTH CARE; HEALTH SURVEY; HUMAN; INTESTINE METAPLASIA; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 20344365320     PISSN: 17434378     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpgasthep0088     Document Type: Review

References (10)

1. Rudolph RE et al. (2000) Effect of segment length on risk for neoplastic progression in patients with Barrett's esophagus. Ann Intern Med 132: 612-620
2. Johnston MH et al. (1996) The prevalence and clinical characteristics of short segments of specialised intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol 91: 1507-1511
3. Spechler SJ (2000) Barrett's esophagus: an overrated cancer risk factor. Gastroenterology 119: 587-589
4. Shaheen NJ et al. (2000) Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119: 333-338
5. van Sandick JW et al. (1998) Impact of endoscopic biospy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 43: 216-222
6. Macdonald CE et al. (2000) Final results from a ten-year cohort of patients undergoing surveillance for Barrett's metaplasia; little value but major cost. BMJ 321: 1252-1255
7. van der Burgh A et al. (1996) Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 39: 5-8
8. McMannus DT et al. (2004) Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 64: 1561-1569
9. National Institute for Clinical Excellence (2004) Photodynamic therapy for high-grade dysplasia in Barrett's oesophagus. Guidance leaflet IPG082. London, UK: NICE
10. Mandal A et al. (2003) Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK; observational study, Aliment Pharmacol Therap 17: 1319-1324